Gilead's (GILD) Yescarta Shows Positive Results as a First-Line Treatment for Patients With High-Risk Large B-cell Lymphoma
Go back to Gilead's (GILD) Yescarta Shows Positive Results as a First-Line Treatment for Patients With High-Risk Large B-cell Lymphoma| Gilead Sciences (NASDAQ: GILD) | Delayed: 150.56 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $150.56 | 52 Week High | $108.63 | |||
| Open | $150.56 | 52 Week Low | $71.39 | |||
| Day High | $150.56 | P/E | 83.18 | |||
| Day Low | $150.56 | EPS | $1.81 | |||
| Volume | 2,533 | |||||
